ReviewInternational journal of molecular sciences2023
Latest Knowledge on the Role of Vitamin D in Hypertension.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 59 citations in OpenAlex.
- Unveiling the benefits of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients.Journal of translational medicine · 2025Trial
- Standard Doses of Cholecalciferol Reduce Glucose and Increase Glutamine in Obesity-Related Hypertension: Results of a Randomized Trial.International journal of molecular sciences · 2024Trial
- Improved hemodynamic and cardiorespiratory instability with vitamin D supplementation in an obstructive sleep apnea rat models.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Article
- The Vicious Cycle of Diabetic Kidney Disease, Vitamin D Deficiency, and Arterial Hypertension.Healthcare (Basel, Switzerland) · 2026Review
- Precision nutrition for hypertension: tea, coffee, antioxidant vitamins interactions with polygenic risk in multi-ethnic populations.European journal of clinical nutrition · 2026Article
- Hypertension among Middle Eastern and North African adults residing in the United States: addressing equity in health research representation using the All of Us Research Program, 2000-2024.Frontiers in medicine · 2026Article
- Vitamin D and Chronic Disorders: A Review of Metabolic and Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The prevalence of vitamin D deficiency and its association to modifiable risk factors of cardiovascular disease among apparently healthy adults in Central Kerala.Journal of family medicine and primary care · 2025Article
- Comparison of cardiovascular autonomic function and biomarkers between vitamin D insufficient and deficient people with newly diagnosed type 2 diabetes mellitus.Journal of family medicine and primary care · 2025Article
- Perinatal Vitamin D Deficiency Enhances Brown Adipose Tissue Thermogenesis in Weanling Rats.International journal of molecular sciences · 2025Article
- Bone mineral density and cardiovascular diseases: a two-sample Mendelian randomization study.JBMR plus · 2025Article
- Effects of Vitamin D Supplementation on Blood Pressure in Patients With Type 1 Diabetes Mellitus: A Systematic Review of Clinical Trials.Health science reports · 2025Review
- Review
- Effect of pre-conception serum vitamin D level on pregnancy outcomes in women undergoing in vitro fertilization with fresh embryo transfer: a retrospective analysis.Reproductive biology and endocrinology : RB&E · 2025Article
- Article
- Impact of vitamin D supplementation on cognitive impairment in elderly individuals with hypertension.Frontiers in neurology · 2025Article
- Sirtuin 1 mediates the pro-survival effects of vitamin D in angiotensin II-induced hypertrophy of H9c2 cardiomyoblasts.Molecular biology reports · 2024Article
- Candidate SNP Markers Significantly Altering the Affinity of the TATA-Binding Protein for the Promoters of Human Genes Associated with Primary Open-Angle Glaucoma.International journal of molecular sciences · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is the third leading cause of the global disease burden, and while populations live longer, adopt more sedentary lifestyles, and become less economically concerned, the prevalence of hypertension is expected to increase. Pathologically elevated blood pressure (BP) is the strongest risk factor for cardiovascular disease (CVD) and related disability, thus making it imperative to treat this disease. Effective standard pharmacological treatments, i.e., diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blocker (ARBs), beta-adrenergic receptor blockers (BARBs), and calcium channel blockers (CCBs), are available. Vitamin D (vitD) is known best for its role in bone and mineral homeostasis. Studies with vitamin D receptor (VDR) knockout mice show an increased renin-angiotensin-aldosterone system (RAAS) activity and increased hypertension, suggesting a key role for vitD as a potential antihypertensive agent. Similar studies in humans displayed ambiguous and mixed results. No direct antihypertensive effect was shown, nor a significant impact on the human RAAS. Interestingly, human studies supplementing vitD with other antihypertensive agents reported more promising results. VitD is considered a safe supplement, proposing its great potential as antihypertensive supplement. The aim of this review is to examine the current knowledge about vitD and its role in the treatment of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.